Citi analyst Samantha Semenkow initiates coverage on $BioAge Labs (BIOA.US)$ with a buy rating, and sets the target price at $45.
According to TipRanks data, the analyst has a success rate of 38.8% and a total average return of -8.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $BioAge Labs (BIOA.US)$'s main analysts recently are as follows:
BioAge Labs, a clinical-stage biotech centered on developing treatments for metabolic diseases, is advancing its lead asset, azelaprag, an oral small molecule that stimulates the apelin receptor and is currently in development for obesity. The company's shares are considered to have a favorable risk/reward profile leading up to the STRIDES readout. The product's oral formulation and ease of manufacturing, coupled with strong preclinical data, suggest it could have a promising clinical profile for treating obesity.
Initial findings indicate that BioAge Labs' azelaprag shows promise, potentially enhancing weight loss when used alongside GLP-1s, and also contributing to better body composition and higher quality of weight loss. Early data suggest that azelaprag not only facilitates weight reduction but also has a positive effect on muscle.
BioAge Labs, a clinical stage biotechnology firm concentrating on metabolic diseases, is recognized for its lead drug Azelaprag, which stands out due to its unique mechanism that mimics exercise, targeting obesity.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
花旗分析師Samantha Semenkow首次給予$BioAge Labs (BIOA.US)$買入評級，目標價45美元。
根據TipRanks數據顯示，該分析師近一年總勝率為38.8%，總平均回報率為-8.2%。
此外，綜合報道，$BioAge Labs (BIOA.US)$近期主要分析師觀點如下：
生物年齡實驗室是一家臨床階段的生物技術公司，致力於開發治療代謝疾病的治療方法，目前正在推進其主力資產艾澤拉普拉格，這是一種口服小分子，可以刺激阿貝林受體，目前正在用於肥胖的開發。公司股票被認爲具有有利的風險/回報配置，有望在STRIDES報告發布之前走強。該產品的口服制劑和製造便利性，再加上強大的臨床前數據，表明它可能在治療肥胖方面具有有希望的臨床特性。
初步發現表明，生物年齡實驗室的艾澤拉普拉格顯示出潛力，可能在與GLP-1s一起使用時增強減重效果，並且有助於改善體成分和提高減重質量。早期數據表明，艾澤拉普拉格不僅有助於減輕體重，還對肌肉有積極影響。
生物年齡實驗室是一家臨床階段的生物技術公司，專注於代謝性疾病，以其獨特的模擬運動機制脫穎而出，致力於研究肥胖。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
